Le Lézard
Classified in: Health
Subject: FEA

The Dohmen Company Foundation Purchases Historic Fein Brothers Building


MILWAUKEE, Wis., Dec. 10, 2020 /PRNewswire/ -- The Dohmen Company Foundation has purchased the former Fein Brothers Building at 2007 N. Dr. Martin Luther King Jr. Drive for its future headquarters. The foundation plans to move into the building in 2021 following a significant renovation to restore the nearly 34,000-square-foot building back to its original beauty.

Dohmen Company Foundation to move headquarters to 2007 N. Dr. Martin Luther King Jr. Drive, Fein Brothers Building.

"This is the perfect location for us for many reasons," says Kathy Koshgarian, President and Chief Operating Officer, "Dohmen has called Milwaukee home for the past 162 years, so we're honored to be able to preserve an iconic piece of Milwaukee's rich architectural history and to become part of a vibrant community like Bronzeville. We're also very much looking forward to collaborating with our new neighbors to realize our vision of healthy communities powered by healthy people."

The new space will serve a dual purpose as both Dohmen's new organizational headquarters as well as the home of its Food For Health program. Food For Health is a program designed to use medically tailored meals to reverse chronic disease, and is currently in beta with Common Ground Healthcare Cooperative.

"Close to 80% of our $3.6 trillion annual healthcare spend in this country is spent treating chronic disease that is entirely preventable; and the trend line is going the wrong direction, with rising rates of diabetes, heart disease and obesity," Koshgarian says. "We believe the way to course correct is to allocate more dollars to preventive interventions like food, rather than allowing people to develop health problems requiring expensive medical treatment."

With nearly 20 years of health care experience, almost 10 of those with Dohmen, Koshgarian brings unique insight to her new leadership role. "I can personally attest to the power of addressing chronic health issues with food and lifestyle changes," she says. "I've seen the results first hand. I'm proud to lead an organization that sees the importance of empowering all people with the tools they need to lead a healthy life, because healthy communities are powered by healthy people."

About the Dohmen Company Foundation

With more than 162-years of healthcare experience, Dohmen has found a way to combine the rigor of business with the heart of philanthropy, becoming the first organization in the nation to transition from a family-owned S-Corporation to a foundation-owned philanthropic enterprise. Today, instead of creating shareholder return, Dohmen is focused on creating social return by investing in healthy communities powered by healthy people, through its own community programs, programs delivered by partner organizations and its portfolio of social businesses.

Dohmen Contact:
Kyle Cherek
(414) 501-5304
[email protected]

SOURCE The Dohmen Company Foundation


These press releases may also interest you

19 mai 2024
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

19 mai 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

19 mai 2024
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

19 mai 2024
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

19 mai 2024
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

19 mai 2024
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...



News published on and distributed by: